Total Funding
1
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
ProteoTech is a drug development company that offers therapeutics and diagnostics for amyloid diseases.
Dennis L. McCurley: Chief Operations Officer- Stephen Runnels: Chief Executive Officer and Director
About the Company
ProteoTech, Inc., also known as Proteoglycan Technologies, Inc., operates as a drug development company in the United States. The company offers therapeutics and diagnostics for amyloid diseases. Its products include Exebryl-1, a molecule compound to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein,
as well as amyloid plaques found in Alzheimer's brains of disease victims; PeptiClere, a nasal spray for the treatment of Alzheimer's disease; Synuclere for the treatment of Parkinson's disease; and Systebryl, a small molecule compound for the treatment of systemic amyloidosis associated with type 2 diabetes. ProteoTech, Inc. was founded in 1996 and is headquartered in Kirkland, Washington.
